News Archives for Position Statements

Recent News

ASGCT Statement on Germline Gene Editing Practices
November 26, 2018
Position Statements

The American Society of Gene & Cell Therapy (ASGCT) considers it wholly unacceptable to use germline gene-editing and the implantation of gene-edited embryos to achieve a pregnancy without extensive research into the safety, efficacy, and legality of such applications. Any announcements of, or claims to have begun suchstudies in germline gene editing are compromised, both ethically and scientifically.

ASGCT Supports NIH/RAC Recommendation

While the RAC serves a valuable role as an essential public forum for science, safety, and ethics, the current requirements for gene therapies have proven redundant.

ASGCT Releases White Paper Addressing the Value of Gene Therapy

The American Society of Gene & Cell Therapy has issued a white paper addressing the value of current and future gene therapies approved for clinical use in the United States.

ASGCT Submits Comments on FDA Draft Guidance on Regenerative Medicine Expedited Programs

ASGCT expressed appreciation for guidance titled, “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions," especially on the Regenerative Medicine Advanced Therapy (RMAT) designation and the inclusion of certain gene therapies in the eligibility for consideration for RMAT designation.

ASGCT Policy Summit
November 4 – 6 | Washington D.C.